Last year, Ashtons was involved in a safety study for the MHRA, which involved monitoring the side effects of different formulations of quetiapine tablets.
This year, we have been asked to carry out a similar study concerned with monitoring the side effects of asenapine (Sycrest®) which is an antipsychotic licensed to treat manic episodes associated with bipolar in adults.
Under no circumstance will Ashtons staff approach patients directly about participating in this study.
If a patient is prescribed asenapine, the pharmacist will provide the patient’s consultant with details of the study, including the protocol and a consent form for the patient. If the patient consents, the pharmacist will carry out the study, which involves completing two questionnaires using the patient’s care notes.
For further information, please contact: